Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › durvalumab

durvalumab

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of durvalumab

74 trials tracked of durvalumab: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 206 citations.

74Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 8 Phase 2 54 Phase 1 7 Other / NA 3
  1. Phase 3 Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) Completed · 206 cited
  2. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 54 cited
  3. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 43 cited
  4. Phase 3 Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer Completed · 1 cited
  5. Phase 4 Durvalumab Long-Term Safety and Efficacy Study Completed
  6. Phase 4 Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC Completed
Show 44 more trials
  1. Phase 3 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Completed
  2. Phase 3 Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. Completed
  3. Phase 3 Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Completed
  4. Phase 3 A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  5. Phase 2 Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed
  6. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  7. Phase 2 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Completed
  8. Phase 2 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Completed
  9. Phase 2 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Completed
  10. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  11. Phase 2 Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
  12. Phase 2 A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies Completed
  13. Phase 2 Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer Completed
  14. Phase 2 Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy Completed
  15. Phase 2 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer Completed
  16. Phase 2 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies Completed
  17. Phase 2 Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Completed
  18. Phase 2 A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed
  19. Phase 2 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin Completed
  20. Phase 2 Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Completed
  21. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  22. Phase 2 A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Completed
  23. Phase 2 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed
  24. Phase 2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Completed
  25. Phase 2 A Study of Durvalumab (MEDI4736) in Esophageal Cancer Completed
  26. Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed
  27. Phase 2 An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer Completed
  28. Phase 2 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Completed
  29. Phase 2 A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. Completed
  30. Phase 2 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Completed
  31. Phase 2 Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer Completed
  32. Phase 2 Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma Completed
  33. Phase 2 Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer Completed
  34. Phase 2 A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Completed
  35. Phase 2 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed
  36. Phase 2 Durvalumab in HIV-1 Patients With Solid Tumors Completed
  37. Phase 2 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed
  38. Phase 2 Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer Completed
  39. Phase 2 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach Completed
  40. Phase 2 Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Completed
  41. Phase 2 A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Completed
  42. Phase 2 Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Completed
  43. Phase 2 CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Completed
  44. Phase 2 An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) Completed

Showing the 50 most-cited and recently-updated of 74 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Gastroenterology Phase II
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Apr 12, 2026
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
Oncology Phase II
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
Apr 10, 2026
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Oncology Meta-analysis
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Frontiers Apr 9, 2026
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
Diabetes & Endocrinology Meta-analysis
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…
Frontiers Apr 9, 2026
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Pulmonology & Critical Care Phase II
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…
Apr 6, 2026